64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

EJNMMI Research

Volumn 5, Issue 1, 2015, Pages

  Kurihara, Hiroaki ^a   Hamada, Akinobu ^b   Yoshida, Masayuki ^a   Shimma, Schuichi ^b   Hashimoto, Jun ^a   Yonemori, Kan ^a   Tani, Hitomi ^a   Miyakita, Yasuji ^a   Kanayama, Yousuke ^c   Wada, Yasuhiro ^c   Kodaira, Makoto ^a   Yunokawa, Mayu ^a   Yamamoto, Harukaze ^a   Shimizu, Chikako ^a   Takahashi, Kazuhiro ^c   Watanabe, Yasuyoshi ^c   Fujiwara, Yasuhiro ^a   Tamura, Kenji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c RIKEN   (Japan)

Author keywords

64Cu; Brain metastasis; HER2 positive breast cancer; PET; Trastuzumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; TETRAXETAN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET NIPPLE DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOACTIVITY; TANDEM MASS SPECTROMETRY;

EID: 84938061527     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-015-0082-6     Document Type: Article

References (26)

1. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.
2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.
3. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22:1063–70.
4. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323–33.
5. Lebeau A, Turzynski A, Braun S, Behrhof W, Fleige B, Schmitt WD, et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol. 2010;28:3264–70.
6. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol. 2011;22:1547–53.
7. Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artifact? Insights through meta-analysis. Breast Cancer Res Treat. 2011;129:659–74.
8. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti- HER2 diabody. Cancer Res. 2005;65:1471–8.
9. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586–92.
10. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013;54:1869–75.
11. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol. 2003;14:1072–7.
12. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608–17.
13. Ono M, Ando M, Yunokawa M, Nakano E, Yonemori K, Matsumoto K, et al. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol. 2009;14:48–52.
14. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, Ono M, et al. Immunohistochemical profiles of brain metastases from breast cancer. J Neurooncol. 2008;90:223–8.
15. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009;27:5278–86.
16. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11:352–63.
17. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007;12:884–98.
18. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50 Suppl 3:814–9.
19. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, et al. The pharmacology of monoclonal antibodies. Ann NY Acad Sci. 1987;507:199–210.
20. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med. 1990;31:1191–8.
21. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs. 2007;18:23–8.
22. Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev. 2013;39:261–9.
23. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer. 2010;116:302–8.
24. Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood–brain barrier. MAbs. 2011;3:153–60.
25. Muro H, Shirasawa H, Maeda M, Nakamura S. Fc receptors of liver sinusoidal endothelium in normal rats and humans. A histologic study with soluble immune complexes. Gastroenterology. 1987;93:1078–85.
26. 64Cu-DOTA-trastuzumab PET. J Nucl Med. 2014;55:23–9.